Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous depigmented polymerized Phleum pratense pollen immunotherapy for grass pollen hypersensitivity
2006-005868-10Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- Apr 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of depigmented polymerized phleum pratense pollen extract in allergic rhinoconjunctivitis (ARC) and grass pollen allergy (2 arms), sponsored by LETI Pharma. Primary endpoint: Total symptom score. Started Apr 2007; status: completed.
02
Drugs
depigmented polymerized phleum pratense pollen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)grass pollen allergy
Beyond the preview
Go deeper on 2006-005868-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005868-10.